immediate treatment with corticosteroids

Phase 3Small molecule

FFondation Ophtalmologique Adolphe de Rothschild

immediate treatment with corticosteroids is one of 8 small molecule programs targeting Asthenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstheniaActive, not recruiting

AstheniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Asthenia

#DrugCompanyPhaseTrials

Ritalin

Novartis

Phase 3

1 2

Rysodeg

Rayos

1 4

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Phase 2

1 5

Ranquilon

VValenta Pharm JSC

Phase 3

1 6

Prospekta

MMateria Medica Holding

Phase 3

1 7

immediate treatment with corticosteroids

FFondation Ophtalmologique Adolphe de Rothschild

Phase 3

1 8

Eptacog Alfa

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Asthenia

NCT06342544

Clinical

Trials by Indication[1]

Asthenia1 trial

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.

Recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT06342544·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for immediate treatment with corticosteroids. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — immediate treatment with corticosteroids compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for immediate treatment with corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondation Ophtalmologique Adolphe de Rothschild company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFondation Ophtalmologique Adolphe de Rothschild

immediate treatment with corticosteroids

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Asthenia1 trial

References

Drug Info

Quick Facts

Related News